arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Camp4 Therapeutics Corp

CAMP

$4.24 ▼ -0.21 (-4.61%) at close

14 Visible periods

23 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Camp4 Therapeutics Corp faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $245.6M

Dividend Yield —

Revenue Growth 50.8%

Op. Margin —

ROIC -33.4% ↘

FCF / Share $-0.19

Trailing P/E —

Price / Book 7.1x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

14-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$1.29M

↑ +50.8% —

Net Income Profit after all expenses

$-18.33M

↓ -47.4% —

FCF / Share Free cash flow per share

$-0.19

↑ +73.8% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↓

Dividend History

Dividend / share · sourced from SEC filings

$0.00 Latest / share

FY 2022

FY 2023

FY 2024

$0.00

FY 2025

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Revenue Growth YoY (%)	50.8% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+535%)	—	—	—	—	—	—	—	—	—	—	—	—	—
EPS Growth YoY (%)	48.4% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	N/M	97.7% Excellent → Excellent Stable Year-over-year change in earnings per share Optimal: > 10%	97.6% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	97.7% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	17.2% Good Good Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—
Net Income Growth YoY (%)	-47.4% Weak ↑ Weak Improving Year-over-year change in net income	-203.4% Weak ↓ Weak Declining Year-over-year change in net income	0.2% Caution ↑ Caution Improving Year-over-year change in net income	0.2% Caution ↑ Caution Improving Year-over-year change in net income	0.2% Caution ↑ Caution Improving Year-over-year change in net income	-2.2% Weak Weak Year-over-year change in net income	0.4% Caution Caution Year-over-year change in net income	—	—	—	—	—	—	—
FCF Growth YoY (%)	73.8% Excellent Excellent Year-over-year change in free cash flow	—	—	98.2% Excellent Excellent Year-over-year change in free cash flow	97.0% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
FCF / Net Income (x)	0.60x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	-0.16x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.17x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	—	1.09x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Return on Invested Capital (%)	-33.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-21.2% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-18.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-25.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-20.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-17.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	6.7% Caution ↓ Caution Declining Return earned on debt + equity capital invested Optimal: > 10%	6.8% Caution ↓ Caution Declining Return earned on debt + equity capital invested Optimal: > 10%	7.5% Fair ↓ Fair Declining Return earned on debt + equity capital invested Optimal: > 10%	8.6% Fair Fair Return earned on debt + equity capital invested Optimal: > 10%	8.7% Fair Fair Return earned on debt + equity capital invested Optimal: > 10%	—	—	—
Return on Capital (%) (%)	-12.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-10.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-15.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-25.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-20.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-17.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-63.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	-24.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-59.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-495%)	-84.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-663%)	-21.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-241%)	-31.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-307%)	-24.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-261%)	-21.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-240%)	7.8% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-48%)	8.5% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-44%)	9.2% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-39%)	10.5% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-30%)	11.2% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-25%)	—	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Net Debt (USD)	$-99.21M	$-109.52M	$-75.25M	$-39.05M	$-49.32M	$-64.04M	$-2.53M	—	—	$-38.38M	$-50.47M	—	—	—

📊 What does each share earn? 8 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Revenue per Share (USD)	$0.02	—	$0.03	$0.07	$0.04	—	—	$0.00	$0.00	—	$0.87	—	—	—
Basic EPS, GAAP (USD)	$-0.32	$-0.87	$-0.55	$-0.62	$-0.62	$65.46	$-24.19	$-26.00	$-26.57	$-30.18	$-29.21	—	—	—
Free Cash Flow per Share (USD)	$-0.19	—	$-0.41	$-0.51	$-0.72	—	—	$-28.12	$-23.81	—	—	—	—	—
Dividend per Share (USD)	—	$0.00	$0.00	$0.00	$0.00	—	—	—	—	—	—	—	—	—
Book Value per Share (USD)	$0.60	$0.92	$1.25	$1.98	$2.56	$3.13	$-158.04	$-304.18	$-288.73	$-268.57	$-278.58	—	—	—
Tangible Book Value per Share (USD)	$0.60	$0.92	$1.25	$1.98	$2.56	$3.13	$-158.04	$-304.18	$-288.73	$-268.57	$-278.58	—	—	—
Basic Weighted Avg Shares (shares)	57.92M	—	27.27M	20.16M	20.15M	—	557,437	483,640	468,695	—	400,426	—	—	—
Dividend Payout Ratio (%)	—	0.0% Excellent → Excellent Stable Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent → Excellent Stable Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	—	—	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Working Capital (USD)	$85.57M	$98.58M	$69.81M	$33.75M	$45.23M	$56.78M	$-6.33M	—	—	$32.21M	—	—	—	—
Total Equity (USD)	$30.90M	$47.70M	$58.67M	$39.99M	$51.57M	$63.14M	$-158.97M	$-147.11M	$-135.32M	$-123.73M	$-111.55M	$-100.58M	$-89.27M	$-77.53M

📋 What is driving earnings? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Sales/Revenue/Turnover (USD)	$1.29M	—	$795.00K	$1.50M	$858.00K	—	—	$0.00	$0.00	$0.00	$350.00K	—	—	—
Depreciation Expense (USD)	$520.00K	$372.00K	$416.00K	$430.00K	$421.00K	$418.00K	—	$424.00K	$436.00K	$435.00K	—	—	—	—
Net Income, GAAP (USD)	$-18.33M	$-40.28M	$-12.43M	$-12.43M	$-12.43M	$-13.28M	$-12.46M	$-12.45M	$-12.45M	$-12.99M	$-12.51M	—	—	—
Operating Cash Flow (USD)	$-10.98M	$6.29M	$-11.22M	$-10.34M	$-14.29M	$-11.29M	—	$-13.44M	$-11.14M	$-11.78M	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 14 quarters

Camp4 Therapeutics Corp

Analytical Summary

14-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Dividend History

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CAMP with peers